StreetInsider.com News Articles

Form 8-K Beam Therapeutics Inc. For: Mar 02

Thu, 05 Mar 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260305/26118830.html

Form 8-K Beam Therapeutics Inc. For: Mar 02

Thu, 05 Mar 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260305/26118830.html

H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Tue, 03 Mar 2026 07:21:39 -0500

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

The analyst commented: "On February 24, Beam reported 4Q25 and full-year 2025 results and reiterated a catalyst-rich 2026 across its liver-targeted genetic disease and hematology franchises (link to deck). Highlights: (1) unveiled BEAM-304, a new gene editing program in phenylketonuria (PKU) with an investigational new drug (IND) filing anticipated in 2026; (2) updated data from BEAM-302 in alpha-1 antitrypsin deficiency (AATD) remains on-track for 1Q26 along with details on an FDA-guided potential accelerated pivotal path; (3) biologics license application (BLA) filing for

Form 4 Beam Therapeutics Inc. For: Feb 24 Filed by: Ciaramella Giuseppe

Thu, 26 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260226/26070519.html

Form 4 Beam Therapeutics Inc. For: Feb 24 Filed by: Ciaramella Giuseppe

Thu, 26 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260226/26070519.html

Beam Therapeutics Inc (BEAM) PT Lowered to $40 at Bernstein; 'Shares Still Undervalued'

Thu, 26 Feb 2026 05:52:28 -0500

Bernstein SocGen Group analyst William Pickering lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $40.00 (from $41.00) while maintaining a Outperform rating.

The analyst commented: "Stock bump on financing and PKU is overdue catchup. Shares still undervalued; We believe that PKU makes sense to pursue even without relying on (supposed) FDA flexibility. Much was made of BEAM’s announcement only 1 day after publication of FDA guidelines on the plausible mechanism pathway, even as it’s unclear if said pathway could actually apply to rare but not ultra-rare diseases like this one. Our view is that the incremental opex is

Beam Therapeutics Inc (BEAM) PT Lowered to $40 at Bernstein; 'Shares Still Undervalued'

Thu, 26 Feb 2026 05:52:28 -0500

Bernstein SocGen Group analyst William Pickering lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $40.00 (from $41.00) while maintaining a Outperform rating.

Beam Therapeutics Inc (BEAM) PT Raised to $26 at RBC Capital

Wed, 25 Feb 2026 09:04:37 -0500

RBC Capital analyst Luca Issi raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $26.00 (from $22.00) while maintaining a rating.

Form 144 Beam Therapeutics Inc. Filed by: Ciaramella Giuseppe

Tue, 24 Feb 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260224/26051780.html

Form 144 Beam Therapeutics Inc. Filed by: Ciaramella Giuseppe

Tue, 24 Feb 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260224/26051780.html

Beam Therapeutics Inc (BEAM) PT Raised to $47 at BofA Securities

Tue, 24 Feb 2026 11:49:39 -0500

BofA Securities analyst Alec W. Stranahan raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $47.00 (from $45.00) while maintaining a Buy rating.

The analyst comments "Beam’s 4Q25 print saw updates to their liver-targeted in vivo editing platform with a new program (BEAM-304 for PKU) announced and progress in Pfizer’s collaboration. We think these updates support the long-term value potential from Beam’s technology, with the announced non-dilutive capital agreement helping to fund the pipeline. We still think near-term focus remains on updated phase 1/2 data for BEAM-302 and next steps for clinical development (1Q26e) – we see the recent

Beam Therapeutics Inc (BEAM) PT Raised to $47 at BofA Securities

Tue, 24 Feb 2026 11:49:39 -0500

BofA Securities analyst Alec W. Stranahan raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $47.00 (from $45.00) while maintaining a Buy rating.

Form S-8 Beam Therapeutics Inc.

Tue, 24 Feb 2026 07:23:00 -0500

si-local-file:///var/storage/secattach/20260224/26046666.html

Form S-8 Beam Therapeutics Inc.

Tue, 24 Feb 2026 07:23:00 -0500

si-local-file:///var/storage/secattach/20260224/26046666.html

Form 10-K Beam Therapeutics Inc. For: Dec 31

Tue, 24 Feb 2026 07:11:00 -0500

http://archive.fast-edgar.com/20260224/AE2BD22CZZ2RJ2ZK22TS2CYSHRQTZZ22Z282

Filed on: February 24, 2026

Form 10-K Beam Therapeutics Inc. For: Dec 31

Tue, 24 Feb 2026 07:11:00 -0500

http://archive.fast-edgar.com/20260224/AE2BD22CZZ2RJ2ZK22TS2CYSHRQTZZ22Z282

Filed on: February 24, 2026

Form 8-K Beam Therapeutics Inc. For: Feb 24

Tue, 24 Feb 2026 07:06:00 -0500

si-local-file:///var/storage/secattach/20260224/26046575.html

Form 8-K Beam Therapeutics Inc. For: Feb 24

Tue, 24 Feb 2026 07:06:00 -0500

si-local-file:///var/storage/secattach/20260224/26046575.html

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Tue, 24 Feb 2026 07:01:00 -0500

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026

Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026

Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026

Expected Cash Runway Now into Mid-2029 Through Execution of Key

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Tue, 24 Feb 2026 07:01:00 -0500

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026

Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026

Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026

Expected Cash Runway Now into Mid-2029 Through Execution of Key

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Tue, 24 Feb 2026 07:01:00 -0500

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026

Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026

Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026

Expected Cash Runway Now into Mid-2029 Through Execution of Key

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Tue, 24 Feb 2026 07:01:00 -0500

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026

Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026

Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026

Expected Cash Runway Now into Mid-2029 Through Execution of Key

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Tue, 24 Feb 2026 07:00:00 -0500

$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term

Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD)

CAMBRIGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) today announced that it has entered into a strategic financing agreement with Sixth Street for substantial, long-term, non-dilutive capital to fund the potential launch of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD). The $500 million senior secured credit facility includes

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Tue, 24 Feb 2026 07:00:00 -0500

$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term

Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD)

CAMBRIGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) today announced that it has entered into a strategic financing agreement with Sixth Street for substantial, long-term, non-dilutive capital to fund the potential launch of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD). The $500 million senior secured credit facility includes

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Tue, 24 Feb 2026 07:00:00 -0500

$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term

Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD)

CAMBRIGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) today announced that it has entered into a strategic financing agreement with Sixth Street for substantial, long-term, non-dilutive capital to fund the potential launch of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD). The $500 million senior secured credit facility includes